For early detection of hepatocellular carcinoma in Egyptian patients with chronic hepatitis C virus infection. Mol. Diagn. Ther. 19, 213?20 (2015). 23. Tsang, T. Y. et al. P-glycoprotein enhances radiation-induced apoptotic cell death via the regulation of miR-16 and Bcl-2 expressions in hepatocellular carcinoma cells. Apoptosis 16, 524?35 (2011). 24. Wu, W. L., Wang, W. Y., Yao, W. Q. Li, G. D. Suppressive effects of microRNA16 around the proliferation, invasion and metastasis of hepatocellular carcinoma cells. Int J. Mol. Med. 36, 1713?719 (2015). 25. Geretto, M. et al. Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators. Am. J. Cancer Res. 7, 1350?371 (2017). 26. Catela, I. T., Voss, G., Cornella, H. Ceder, Y. microRNAs as cancer therapeutics: a step closer to clinical application. Cancer Lett. 407, 113?22 (2017). 27. Daher, S., Massarwa, M., Benson, A. A. Khoury, T. Present and future therapy of hepatocellular carcinoma: an updated complete overview. J. Clin. Alopecia areata jak Inhibitors products Transl. Monensin methyl ester In stock Hepatol. six, 69?8 (2018). 28. Sun, T., Liu, H. Ming, L. A number of roles of autophagy in the sorafenib resistance of hepatocellular carcinoma. Cell. Physiol. Biochem. 44, 716?27 (2017). 29. Rao, S. et al. Transforming growth factor-beta in liver cancer stem cells and regeneration. Hepatol. Commun. 1, 477?93 (2017). 30. Ray, E. M. Sanoff, H. K. Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions. J. Hepatocell. Carcinoma 4, 131?38 (2017). 31. Lohitesh, K., Chowdhury, R. Mukherjee, S. Resistance a significant hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer Cell Int. 18, 44 (2018). 32. Zhang, F. Wang, D. The pattern of microRNA binding site distribution. Genes 8, E296 (2017). 33. Pekarsky, Y., Balatti, V. Croce, C. M. BCL2 and miR-15/16: from gene discovery to treatment. Cell Death Differ. 25, 21?6 (2018). 34. Petrovic, N., Davidovic, R., Bajic, V., Obradovic, M. Isenovic, R. E. MicroRNA in breast cancer: the association with BRCA1/2. Cancer Biomark. 19, 119?28 (2017). 35. Cipriano, R. et al. FAM83B mediates EGFR- and RAS-driven oncogenic transformation. J. Clin. Invest. 122, 3197?210 (2012). 36. Tang, Y. et al. Co-upregulation of 14-3-3zeta and P-Akt is related with oncogenesis and recurrence of hepatocellular carcinoma. Cell. Physiol. Biochem. 45, 1097?107 (2018). 37. Gomez-Suarez, M. et al. 14-3-3 Proteins regulate Akt Thr308 phosphorylation in intestinal epithelial cells. Cell Death Differ. 23, 1060?072 (2016). 38. Dietel, E., Brobeil, A., Gattenlohner, S. Wimmer, M. The value from the appropriate framework: mitogen-activated protein kinase pathway plus the scaffolding protein PTPIP51. Int. J. Mol. Sci. 19, E3282 (2018). 39. Guo, H. et al. Plastid ucleus communication entails calcium-modulated MAPK signalling. Nat. Commun. 7, 12173 (2016). 40. Aguilera, C. et al. Efficient nuclear export of p65-IkappaBalpha complexes requires 14-3-3 proteins. J. Cell Sci. 129, 2472 (2016). 41. Porter, G. W., Khuri, F. R. Fu, H. Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin. Cancer Biol. 16, 193?02 (2006). 42. Nava, P. et al. IFNgamma-induced suppression of beta-catenin signaling: proof for roles of Akt and 14.three.3zeta. Mol. Biol. Cell 25, 2894?904 (2014). 43. Dobson, M. et al. Bimodal regulation of FoxO3 by AKT and 14-3-3. Biochim. Biophys. Acta 1813, 1453?464 (2011). 44. Su, C. H. et al. Nuclea.
